首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1402197

全球抗體治療市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global Antibody Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年12月01日 | 出版商:

Value Market Research | 英文 221 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球抗體治療市場需求預計將從 2022 年的 2,591.4 億美元增至 2030 年的近 8,043.8 億美元，2023-2030 年研究期間複合CAGR為 15.21%。

抗體療法，也稱為治療性抗體或生物藥物，是由免疫系統產生的抗體開發的一類藥物。這些抗體可以從動物（主要是小鼠或兔子）中改造或衍生，然後進行修飾以用於治療各種疾病。

市場動態

抗體治療市場受到多種因素的推動，導致其大幅成長。癌症、自體免疫疾病和傳染病等慢性疾病的發生率不斷增加，推動了對抗體療法提供的精確、有針對性的治療的需求。生物技術的進步，特別是抗體工程和製造方面的進步，帶來了更有效、更安全的治療方法，擴大了在不同醫學領域的應用。研發投資，特別是探索新標靶和創新抗體形式，進一步推動市場擴張。向個人化醫療的轉變有利於抗體療法，從而可以為個別患者提供量身定做的治療。成功的臨床試驗和監管部門的批准增強了醫療保健專業人員和患者對這些療法的信心，從而提高了採用率。不斷成長的醫療保健支出、行業參與者之間的合作以及各個醫學領域基於抗體的治療範圍的不斷擴大，共同促進了抗體治療市場的強勁成長，使這些療法處於現代醫學的前沿。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球抗體治療市場的每個細分市場進行了包容性評估。抗體治療行業的成長和趨勢為這項研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲抗體治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。抗體治療市場的主要參與者包括羅氏公司（瑞士）、艾伯維公司（美國）、強生公司（美國）、默克公司（德國）、百時美施貴寶公司（美國）、阿斯特捷利康公司（英國）、賽諾菲（法國）、再生元製藥公司（美國）、諾華公司（瑞士）、安進公司（美國）、百健公司（美國）。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

簡介 - 市場動態
市場促進因素
市場限制
機會
產業動態
波特五力分析
市場吸引力分析
- 按格式分類的市場吸引力分析
- 按疾病領域分類的市場吸引力分析
- 按給藥途徑進行的市場吸引力分析
- 按來源分類的市場吸引力分析
- 最終用戶的市場吸引力分析
- 市場吸引力分析：按地區

第 4 章：價值鏈分析

價值鏈分析
原料分析
- 原料清單
- 原料廠商清單
- 主要原物料價格走勢
潛在買家名單
行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢

第 5 章：全球抗體治療市場分析：依形式

按格式概述
歷史和預測數據
按格式分析
單株抗體
多株抗體抗體治療
雙特異性抗體
抗體片段
其他

第 6 章：全球抗體治療市場分析：依疾病領域

疾病領域概述
歷史和預測數據
按疾病領域分析
自體免疫疾病與發炎性疾病
腫瘤學
血液學
傳染性疾病
骨科
免疫學
神經病學
其他

第 7 章：全球抗體治療市場分析：依給藥途徑

依給藥途徑概述
歷史和預測數據
依給藥途徑分析
靜脈
皮下
其他

第 8 章：全球抗體治療市場分析：依來源分類

按來源概述
歷史和預測數據
按來源分析
人類
人性化
嵌合體
其他

第 9 章：全球抗體治療市場分析：依最終使用者分類

最終用戶概述
歷史和預測數據
最終用戶分析
醫院
長期照護設施
其他

第 10 章：全球抗體治療市場分析：依地理位置

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 11 章：抗體治療公司的競爭格局

抗體治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 12 章：公司簡介

公司股份分析
市場集中度
F. Hoffmann-La Roche Ltd. (Switzerland)

公司簡介
公司收入
產品
最近的發展

AbbVie Inc. (US)

公司簡介
公司收入
產品
最近的發展

Johnson & Johnson (US)

公司簡介
公司收入
產品
最近的發展

Merck KGaA (Germany)

公司簡介
公司收入
產品
最近的發展

Bristol-Myers Squibb (US)

公司簡介
公司收入
產品
最近的發展

AstraZeneca (UK)

公司簡介
公司收入
產品
最近的發展

Sanofi (France)

公司簡介
公司收入
產品
最近的發展

Regeneron Pharmaceuticals Inc. (US)

公司簡介
公司收入
產品
最近的發展

Novartis AG (Switzerland)

公司簡介
公司收入
產品
最近的發展

Amgen Inc. (US)

公司簡介
公司收入
產品
最近的發展

Biogen Inc. (US)

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113173

The global demand for Antibody Therapeutics Market is presumed to reach the market size of nearly USD 804.38 BN by 2030 from USD 259.14 BN in 2022 with a CAGR of 15.21% under the study period 2023 - 2030.

Antibody therapeutics, also known as therapeutic antibodies or biological drugs, are a class of medications developed from antibodies produced by the immune system. These antibodies can be engineered or derived from animals, primarily mice or rabbits, and then modified to be used as treatments for various diseases.

MARKET DYNAMICS

The Antibody therapeutics market is driven by various factors contributing to its substantial growth. Increasing incidences of chronic diseases like cancer, autoimmune disorders, and infectious ailments fuel the demand for precise, targeted treatments that antibody therapies offer. Advancements in biotechnology, particularly in antibody engineering and manufacturing, lead to more effective and safer therapies, expanding their applications across diverse medical fields. Investments in research and development, especially in exploring new targets and innovative antibody formats, further propel market expansion. The shift toward personalized medicine favors antibody therapeutics, allowing tailored treatments for individual patients. Successful clinical trials and regulatory approvals bolster confidence in these therapies among healthcare professionals and patients, driving adoption rates. Rising healthcare expenditure, collaborations among industry players, and the broadening scope of antibody-based treatments in various medical domains collectively contribute to the robust growth of the Antibody therapeutics market, positioning these therapies at the forefront of modern medicine.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of antibody therapeutics. The growth and trends of antibody therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the antibody therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Format

Monoclonal Antibody
Polyclonal Antibody Therapy
Bispecific Antibody
Antibody Fragment
Other

By Disease Areas

Autoimmune & Inflammatory Diseases
Oncology
Hematology
Infectious Diseases
Osteology
Immunology
Neurology
Other

By Route Of Administration

Intravenous
Subcutaneous
Other

By Source

Human
Humanized
Chimeric
Other

By End User

Hospitals
Long-Term Care Facilities
Other

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antibody Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antibody Therapeutics market include F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ANTIBODY THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Format
- 3.7.2 Market Attractiveness Analysis By Disease Areas
- 3.7.3 Market Attractiveness Analysis By Route Of Administration
- 3.7.4 Market Attractiveness Analysis By Source
- 3.7.5 Market Attractiveness Analysis By End User
- 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY FORMAT

5.1 Overview by Format
5.2 Historical and Forecast Data
5.3 Analysis by Format
5.4 Monoclonal Antibody Historic and Forecast Sales by Regions
5.5 Polyclonal Antibody Therapy Historic and Forecast Sales by Regions
5.6 Bispecific Antibody Historic and Forecast Sales by Regions
5.7 Antibody Fragment Historic and Forecast Sales by Regions
5.8 Other Historic and Forecast Sales by Regions

6 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY DISEASE AREAS

6.1 Overview by Disease Areas
6.2 Historical and Forecast Data
6.3 Analysis by Disease Areas
6.4 Autoimmune & Inflammatory Diseases Historic and Forecast Sales by Regions
6.5 Oncology Historic and Forecast Sales by Regions
6.6 Hematology Historic and Forecast Sales by Regions
6.7 Infectious Diseases Historic and Forecast Sales by Regions
6.8 Osteology Historic and Forecast Sales by Regions
6.9 Immunology Historic and Forecast Sales by Regions
6.10. Neurology Historic and Forecast Sales by Regions
6.11 Other Historic and Forecast Sales by Regions

7 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1 Overview by Route Of Administration
7.2 Historical and Forecast Data
7.3 Analysis by Route Of Administration
7.4 Intravenous Historic and Forecast Sales by Regions
7.5 Subcutaneous Historic and Forecast Sales by Regions
7.6 Other Historic and Forecast Sales by Regions

8 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY SOURCE

8.1 Overview by Source
8.2 Historical and Forecast Data
8.3 Analysis by Source
8.4 Human Historic and Forecast Sales by Regions
8.5 Humanized Historic and Forecast Sales by Regions
8.6 Chimeric Historic and Forecast Sales by Regions
8.7 Other Historic and Forecast Sales by Regions

9 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY END USER

9.1 Overview by End User
9.2 Historical and Forecast Data
9.3 Analysis by End User
9.4 Hospitals Historic and Forecast Sales by Regions
9.5 Long-term Care Facilities Historic and Forecast Sales by Regions
9.6 Other Historic and Forecast Sales by Regions

10 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Data Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Data Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Data Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. South East Asia Sales Analysis
- 10.5.10. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Data Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Data Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE ANTIBODY THERAPEUTICS COMPANIES

11.1. Antibody Therapeutics Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF ANTIBODY THERAPEUTICS INDUSTRY

12.1. Company Share Analysis
12.2. Market Concentration Rate
12.3. F. Hoffmann-La Roche Ltd. (Switzerland)
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. AbbVie Inc. (US)
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. Johnson & Johnson (US)
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. Merck KGaA (Germany)
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. Bristol-Myers Squibb (US)
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. AstraZeneca (UK)
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Sanofi (France)
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Regeneron Pharmaceuticals Inc. (US)
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Novartis AG (Switzerland)
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments
12.12. Amgen Inc. (US)
- 12.12.1. Company Overview
- 12.12.2. Company Revenue
- 12.12.3. Products
- 12.12.4. Recent Developments
12.13. Biogen Inc. (US)
- 12.13.1. Company Overview
- 12.13.2. Company Revenue
- 12.13.3. Products
- 12.13.4. Recent Developments